MCID: CRV031
MIFTS: 53

Cervical Adenocarcinoma

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Cervical Adenocarcinoma

MalaCards integrated aliases for Cervical Adenocarcinoma:

Name: Cervical Adenocarcinoma 12 60 56 15 17 74
Adenocarcinoma of the Uterine Cervix 12
Adenocarcinoma of the Cervix Uteri 60
Adenocarcinoma Cervix Uteri 12
Adenocarcinoma of Cervix 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3702
NCIt 51 C4029
ICD10 via Orphanet 35 C53.0 C53.1 C53.8
UMLS via Orphanet 75 C0279672
Orphanet 60 ORPHA213772
UMLS 74 C0279672

Summaries for Cervical Adenocarcinoma

Disease Ontology : 12 A cervix carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Cervical Adenocarcinoma, also known as adenocarcinoma of the uterine cervix, is related to glassy cell carcinoma of the cervix and adenocarcinoma. An important gene associated with Cervical Adenocarcinoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Gastric cancer. The drugs Cisplatin and Vaccines have been mentioned in the context of this disorder. Affiliated tissues include cervix, breast and lymph node, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Cervical Adenocarcinoma

Diseases in the Cervical Adenocarcinoma family:

Early Invasive Cervical Adenocarcinoma

Diseases related to Cervical Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 277)
# Related Disease Score Top Affiliating Genes
1 glassy cell carcinoma of the cervix 32.8 ERBB2 ESR1
2 adenocarcinoma 31.4 CDKN2A ERBB2 PTGS2 TP53
3 appendix adenocarcinoma 31.1 CDX2 KRT20 KRT7
4 adenocarcinoma in situ 31.0 CDKN2A CDX2 KRT20 KRT7
5 mucinous adenocarcinoma 31.0 CDKN2A CDX2 KRT20 KRT7
6 papillary serous adenocarcinoma 30.8 KRT20 KRT7 TP53
7 signet ring cell adenocarcinoma 30.6 CDX2 KRT20 KRT7
8 endocervical adenocarcinoma 30.4 CDKN2A CDX2 KRT20 KRT7 TP53
9 squamous cell carcinoma 30.2 CDKN2A ERBB2 PTGS2 TP53
10 cervical squamous cell carcinoma 30.1 CDKN2A RASSF1 TP53
11 papillary transitional carcinoma 29.9 KRT20 KRT7
12 suppressor of tumorigenicity 3 29.8 CDKN1A CDKN2A TP53
13 papillary adenocarcinoma 29.7 ERBB2 KRT7 TP53
14 small cell carcinoma 29.7 CDKN2A KRT20 KRT7 TP53
15 ovarian cancer 1 29.5 ERBB2 KRT7 TP53
16 vulval paget's disease 29.5 CDKN2A ERBB2 KRT20 KRT7
17 transitional cell carcinoma 29.4 CDKN2A ERBB2 KRT20 KRT7 PTGS2 TP53
18 papilloma 29.4 CDKN1A CDKN2A KRT20 KRT7 TP53
19 mammary paget's disease 29.4 ERBB2 ESR1 KRT20 KRT7
20 endometrial adenocarcinoma 29.1 CDKN2A ERBB2 ESR1 KRT7 TP53
21 gastric cancer 29.1 CDKN1A CDKN2A CDX2 ERBB2 KRT20 PTGS2
22 lung cancer 28.4 CDKN1A CDKN2A ERBB2 KRT20 KRT7 PTGS2
23 endometrial cancer 28.3 CDKN1A CDKN2A EBAG9 ERBB2 ESR1 KRT7
24 early invasive cervical adenocarcinoma 12.5
25 cervical mucinous adenocarcinoma 11.1
26 cervical clear cell adenocarcinoma 11.1
27 wolffian duct adenocarcinoma 11.1
28 cervical serous adenocarcinoma 11.1
29 cervical endometrioid adenocarcinoma 11.1
30 balanitis xerotica obliterans 10.5 CDKN2A PTGS2
31 bowenoid papulosis 10.5 CDKN2A PTGS2
32 bile reflux 10.5 CDX2 PTGS2
33 anal canal carcinoma 10.5 CDKN2A KRT7
34 duodenum adenocarcinoma 10.5 CDX2 KRT7
35 anal canal adenocarcinoma 10.5 CDX2 KRT7
36 epithelial predominant wilms' tumor 10.5 CDX2 KRT7
37 large intestine adenocarcinoma 10.5 KRT20 KRT7
38 thyroid lymphoma 10.5 CDKN2A TP53
39 bladder lymphoma 10.5 KRT20 KRT7
40 megaesophagus 10.5 CDKN2A TP53
41 vulva squamous cell carcinoma 10.5 CDKN2A TP53
42 scrotal carcinoma 10.5 CDKN2A TP53
43 linitis plastica 10.5 KRT20 KRT7
44 bladder squamous cell carcinoma 10.5 CDKN2A TP53
45 bile duct cystadenocarcinoma 10.5 KRT20 KRT7
46 medulloepithelioma 10.5 KRT20 KRT7
47 adenoid squamous cell carcinoma 10.5 KRT20 KRT7
48 keratinizing squamous cell carcinoma 10.5 CDKN2A TP53
49 anal squamous cell carcinoma 10.5 CDKN2A TP53
50 gastric adenosquamous carcinoma 10.5 CDKN2A TP53

Graphical network of the top 20 diseases related to Cervical Adenocarcinoma:



Diseases related to Cervical Adenocarcinoma

Symptoms & Phenotypes for Cervical Adenocarcinoma

GenomeRNAi Phenotypes related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.7 CDKN1A CDKN2A EBAG9 LAMC2 MCM5 TP53
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.7 CDKN1A CDKN2A EBAG9 LAMC2 MCM5 TP53

MGI Mouse Phenotypes related to Cervical Adenocarcinoma:

47 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.22 CDKN1A CDKN2A CDX2 ERBB2 ESR1 KRT7
2 digestive/alimentary MP:0005381 10.16 CDKN1A CDKN2A CDX2 ERBB2 ESR1 LAMC2
3 homeostasis/metabolism MP:0005376 10.16 CDKN1A CDKN2A CDX2 ERBB2 ESR1 KRT7
4 cardiovascular system MP:0005385 10.14 CDKN1A CDKN2A CDX2 ERBB2 ESR1 PTGS2
5 endocrine/exocrine gland MP:0005379 10.08 CDKN1A CDKN2A CDX2 ERBB2 ESR1 PTGS2
6 embryo MP:0005380 10.04 CDKN1A CDKN2A CDX2 ERBB2 ESR1 PTGS2
7 integument MP:0010771 9.98 CDKN1A CDKN2A ERBB2 ESR1 LAMC2 PTGS2
8 neoplasm MP:0002006 9.92 CDKN1A CDKN2A CDX2 ERBB2 ESR1 PTGS2
9 limbs/digits/tail MP:0005371 9.88 CDKN1A CDX2 ERBB2 ESR1 LAMC2 TP53
10 liver/biliary system MP:0005370 9.85 CDKN1A CDKN2A ESR1 PTGS2 RASSF1 TP53
11 normal MP:0002873 9.8 CDX2 ERBB2 ESR1 PTGS2 RASSF1 TP53
12 renal/urinary system MP:0005367 9.63 CDKN1A ESR1 KRT7 LAMC2 PTGS2 TP53
13 respiratory system MP:0005388 9.5 CDKN1A CDKN2A ERBB2 ESR1 LAMC2 PTGS2
14 skeleton MP:0005390 9.23 CDKN1A CDKN2A CDX2 ERBB2 ESR1 LAMC2

Drugs & Therapeutics for Cervical Adenocarcinoma

Drugs for Cervical Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 118)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
2 Vaccines Phase 4,Phase 3,Phase 2
3 Epoetin alfa Phase 4,Phase 3 113427-24-0
4 Hematinics Phase 4,Phase 3
5
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
6
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
7
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
8
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
9
Vinorelbine Approved, Investigational Phase 3 71486-22-1 44424639 60780
10
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
11
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
12
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
13
leucovorin Approved Phase 3,Phase 2 58-05-9 143 6006
14
Ifosfamide Approved Phase 3 3778-73-2 3690
15
Vinblastine Approved Phase 3 865-21-4 241903 13342
16
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
17
Fluorouracil Approved Phase 3,Phase 1,Phase 2 51-21-8 3385
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
19
Tirapazamine Investigational Phase 3,Phase 1 27314-97-2
20 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
21 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
22 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1
23 Antimitotic Agents Phase 3,Phase 2,Phase 1
24 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
25 Antiviral Agents Phase 3,Phase 2,Phase 1
26 Immunologic Factors Phase 3,Phase 2,Phase 1
27 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
28 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
29 Angiogenesis Inhibitors Phase 3,Phase 2
30 Antibodies Phase 3,Phase 2,Phase 1
31 Immunoglobulin G Phase 3,Phase 2,Phase 1
32 Immunoglobulins Phase 3,Phase 2,Phase 1
33 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
34 Endothelial Growth Factors Phase 3,Phase 2
35 Mitogens Phase 3,Phase 2
36 Angiogenesis Modulating Agents Phase 3,Phase 2
37 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
38 Antimetabolites Phase 3,Phase 2,Phase 1
39 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
40 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
41
Isophosphamide mustard Phase 3 0
42 Antirheumatic Agents Phase 3,Phase 1,Phase 2
43 Dermatologic Agents Phase 3
44 Vitamin B Complex Phase 3,Phase 2
45 Anti-Bacterial Agents Phase 3,Phase 2
46 Folic Acid Antagonists Phase 3,Phase 2
47 Alkylating Agents Phase 3,Phase 2
48 Folate Phase 3,Phase 2
49 Vitamin B9 Phase 3,Phase 2
50 Mitomycins Phase 3

Interventional clinical trials:

(show top 50) (show all 99)
# Name Status NCT ID Phase Drugs
1 V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Completed NCT01544478 Phase 4
2 Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Completed NCT00046969 Phase 4 cisplatin
3 Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041) Completed NCT00834106 Phase 3
4 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00803062 Phase 3 Cisplatin;Paclitaxel;Topotecan Hydrochloride
5 Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Completed NCT00064077 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
6 Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer Completed NCT00003209 Phase 3 cisplatin;fluorouracil;ifosfamide;methotrexate;mitomycin C;vinblastine sulfate;vindesine
7 Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00003945 Phase 3 cisplatin;topotecan hydrochloride
8 Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia Completed NCT00017004 Phase 3 Cisplatin
9 Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix Completed NCT00003078 Phase 3 cisplatin;fluorouracil
10 Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer Recruiting NCT02466971 Phase 3 Cisplatin;Triapine
11 Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Recruiting NCT01101451 Phase 3 Cisplatin
12 Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Recruiting NCT00980954 Phase 3 carboplatin;cisplatin;paclitaxel
13 A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213) Active, not recruiting NCT03493542 Phase 3
14 Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer Active, not recruiting NCT02853604 Phase 3 ADXS11-001;Placebo
15 Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Active, not recruiting NCT01414608 Phase 3 Carboplatin;Cisplatin;Paclitaxel
16 Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy in Patients With Stage IB or II Cervical Cancer Active, not recruiting NCT00039338 Phase 3 cisplatin
17 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Active, not recruiting NCT01672892 Phase 3
18 Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix Terminated NCT00054067 Phase 3 cisplatin
19 Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer Terminated NCT00262821 Phase 3 cisplatin;tirapazamine
20 Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer Terminated NCT00085631 Phase 3 cisplatin
21 Cisplatin Combined With Radiation Therapy and Hyperthermia in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer Unknown status NCT00008112 Phase 2 cisplatin
22 Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer Unknown status NCT01158248 Phase 2 cisplatin
23 Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Unknown status NCT00462397 Phase 2 carboplatin;cisplatin;paclitaxel
24 Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application Completed NCT01639625 Phase 2 CIGB300
25 Ixabepilone to Treat Cervical Cancer Completed NCT00924066 Phase 2 Ixempra (Ixabepilone (BMS-247550) )
26 Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00039442 Phase 2 Capecitabine
27 ADXS11-001 High Dose HPV+ Cervical Cancer Completed NCT02164461 Phase 1, Phase 2
28 Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer Completed NCT02562729 Phase 2
29 Phase II Study of HPV Therapeutic Vaccine in HPV Infected Women With Normal Cytology or ASCUS/LSIL Completed NCT01957878 Phase 2
30 Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT01267253 Phase 2 Brivanib Alaninate
31 Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery Completed NCT00389974 Phase 2 sunitinib malate
32 ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00309959 Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
33 Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer Completed NCT00217633 Phase 2
34 Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer Completed NCT00002562 Phase 2 paclitaxel
35 Arsenic Trioxide in Treating Patients With Stage IVB or Recurrent Cervical Cancer Completed NCT00005999 Phase 2 arsenic trioxide
36 Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer Completed NCT00057863 Phase 2 Paclitaxel;Oxaliplatin
37 Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer Completed NCT00005070 Phase 2 irofulven
38 Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix Completed NCT00003017 Phase 2
39 Surgery and Vaccine Therapy in Treating Patients With Early Cervical Cancer Completed NCT00002916 Phase 2
40 Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix Completed NCT00003065 Phase 2 paclitaxel;topotecan hydrochloride
41 Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT01266447 Phase 2 Topotecan Hydrochloride;Veliparib
42 Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery Completed NCT01026792 Phase 2 Temsirolimus
43 FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer Completed NCT00559377 Phase 2
44 Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
45 Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer Completed NCT00369122 Phase 2 Cisplatin
46 Carboplatin and Paclitaxel With or Without Cediranib Maleate in Treating Patients With Metastatic or Recurrent Cervical Cancer That Cannot Be Removed by Surgery Completed NCT01229930 Phase 2 carboplatin;cediranib maleate;paclitaxel
47 Carboplatin and Topotecan in Treating Patients With Relapsed or Metastatic Cervical Cancer Completed NCT00807079 Phase 1, Phase 2 carboplatin;topotecan hydrochloride
48 Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage IB, Stage II, or Stage IIIB Cervical Cancer Completed NCT00957411 Phase 2 cisplatin
49 Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer Completed NCT00012012 Phase 1, Phase 2 Amifostine trihydrate;Cisplatin
50 Dose Escalation Study of Simultaneous Boost Intensity-Modulated Radiotherapy for Locally Advanced Cervical Cancer Completed NCT01230996 Phase 1, Phase 2 Cisplatin

Search NIH Clinical Center for Cervical Adenocarcinoma

Genetic Tests for Cervical Adenocarcinoma

Anatomical Context for Cervical Adenocarcinoma

MalaCards organs/tissues related to Cervical Adenocarcinoma:

42
Cervix, Breast, Lymph Node, Ovary, Lung, Testes, Appendix

Publications for Cervical Adenocarcinoma

Articles related to Cervical Adenocarcinoma:

(show top 50) (show all 654)
# Title Authors Year
1
Transtubal Spread of a Superficially Invasive Cervical Adenocarcinoma to the Ovaries After 11 Years. ( 31033802 )
2019
2
Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015. ( 30980692 )
2019
3
FIGO Stage Is the Strongest Prognostic Factor in Adenocarcinoma of the Uterine Cervix. ( 31006541 )
2019
4
Pancreatic Metastasis from Adenocarcinoma of the Uterine Cervix. ( 31013562 )
2019
5
Short-term recurrence and distant metastasis following robotic-assisted radical hysterectomy with pelvic lymphadenectomy and chemoradiotherapy for a stage IB1 cervical adenocarcinoma: A case report and literature review. ( 31027131 )
2019
6
≤ Cyclin D1 protein affecting global women's health by regulating HPV mediated adenocarcinoma of the uterine cervix. ( 30903019 )
2019
7
Cytological diagnosis of a rare case of alpha-fetoprotein producing gastric-type adenocarcinoma of the uterine cervix. ( 30861248 )
2019
8
Micropapillary Cervical Adenocarcinoma: A Clinicopathologic Study of 44 Cases. ( 30864975 )
2019
9
Clinical and MRI Characteristics of Uterine Cervical Adenocarcinoma: Its Variants and Mimics. ( 30799567 )
2019
10
Clinicopathological characteristics of patients with mucinous adenocarcinoma of the uterine cervix: A retrospective study of 21 cases. ( 30807852 )
2019
11
Metastatic cervical adenocarcinoma to the breast: A case report and literature review. ( 30815528 )
2019
12
Adenocarcinoma of the uterine cervix: Pathologic features, treatment options, clinical outcome and prognostic variables. ( 30819439 )
2019
13
Perivascular epithelioid cell tumour and mesonephric adenocarcinoma of the uterine cervix: an unknown co-existence. ( 30697432 )
2019
14
Sellar Metastasis of Cervical Adenocarcinoma. ( 30733881 )
2019
15
Trefoil factor family 2 protein: a potential immunohistochemical marker for aiding diagnosis of lobular endocervical glandular hyperplasia and gastric-type adenocarcinoma of the uterine cervix. ( 30324235 )
2019
16
RANZCOG Fellows' adherence to guidelines following cytological prediction of cervical adenocarcinoma-in-situ: Cause for concern? ( 30284744 )
2019
17
Morphologic Features of Gastric-type Cervical Adenocarcinoma in Small Surgical and Cytology Specimens. ( 29750702 )
2019
18
Pretreatment neutrophil to lymphocyte and platelet to lymphocyte ratios as predictive factors for the survival of cervical adenocarcinoma patients. ( 30538552 )
2018
19
Molecular prognostic factors in early-stage cervical adenocarcinoma. ( 30509055 )
2018
20
Effect of tibolone on the survival of early stage cervical adenocarcinoma patients. ( 30254994 )
2018
21
Estrogen/GPR30 Signaling Contributes to the Malignant Potentials of ER-Negative Cervical Adenocarcinoma via Regulation of Claudin-1 Expression. ( 30227306 )
2018
22
Bioinformatics analysis of methylation in cervical adenocarcinoma in Xinjiang, China. ( 30170437 )
2018
23
Survival benefits with the addition of adjuvant hysterectomy to radiochemotherapy for treatment of stage I-II adenocarcinoma of the uterine cervix. ( 30114328 )
2018
24
Euphornin reduces proliferation of human cervical adenocarcinoma HeLa cells through induction of apoptosis and G2/M cell cycle arrest. ( 30100745 )
2018
25
Disease-free survival after robotic-assisted laparoscopic total pelvic exenteration for recurrent cervical adenocarcinoma: A case report. ( 30045297 )
2018
26
Neoadjuvant Platinum-based Chemotherapy Followed by Radical Hysterectomy for Stage Ib2-IIb Adenocarcinoma of the Uterine Cervix - An Italian Multicenter Retrospective Study. ( 29848719 )
2018
27
MiR-362-3p functions as a tumor suppressor through targeting MCM5 in cervical adenocarcinoma. ( 29871972 )
2018
28
The safety of fertility preservation for microinvasive cervical adenocarcinoma: a meta-analysis and trial sequential analysis. ( 29876746 )
2018
29
Is the ovarian preservation safe in young women with stages IB-IIA villoglandular adenocarcinoma of the uterine cervix? ( 29770624 )
2018
30
Methods for Measuring and Staging a Uterine Cervical Adenocarcinoma Showing Intracystic Papillary Growth: A Case Report. ( 28700431 )
2018
31
Uterine cervical adenocarcinoma associated with lobular endocervical glandular hyperplasia: Radiologic-pathologic correlation. ( 29144012 )
2018
32
Tumor-associated CD204+ M2 macrophages are unfavorable prognostic indicators in uterine cervical adenocarcinoma. ( 29274107 )
2018
33
Clinical outcomes of carbon ion radiotherapy with concurrent chemotherapy for locally advanced uterine cervical adenocarcinoma in a phase 1/2 clinical trial (Protocol 1001). ( 29341491 )
2018
34
Ovarian conservation is associated with better survival in young patients with T1N0M0 cervical adenocarcinoma: a population-based study. ( 29362924 )
2018
35
Cervical Adenocarcinoma: A Comparison of the Reproducibility of the World Health Organization 2003 and 2014 Classifications. ( 29474242 )
2018
36
Postoperative clinicopathological factors affecting cervical adenocarcinoma: Stages I-IIB. ( 29480826 )
2018
37
Concomitant endometrial and cervical adenocarcinoma: A case report and literature review. ( 29505548 )
2018
38
miR-27a inhibits cervical adenocarcinoma progression by downregulating the TGF-βRI signaling pathway. ( 29531222 )
2018
39
Gastric type mucinous endocervical adenocarcinoma of the uterine cervix: very rare and interesting case. ( 29372165 )
2018
40
Multicystic mucinous adenocarcinoma of the uterine cervix compared with benign multicystic lesions: Multiparametric MR features. ( 29624774 )
2018
41
Surgical treatment and outcome of early invasive adenocarcinoma of the uterine cervix (FIGO stage IA1). ( 28429457 )
2018
42
The pattern is the issue: recent advances in adenocarcinoma of the uterine cervix. ( 29404709 )
2018
43
Gastric-Type Adenocarcinoma of the Uterine Cervix: Magnetic Resonance Imaging Features, Clinical Outcomes, and Prognostic Factors. ( 29683881 )
2018
44
Comparison of Cold-Knife Conization versus Loop Electrosurgical Excision for Cervical Adenocarcinoma In Situ (ACIS): A Systematic Review and Meta-Analysis. ( 28125627 )
2017
45
Risk of persistent or recurrent neoplasia in conservatively treated women with cervical adenocarcinoma in situ with negative histological margins. ( 28181670 )
2017
46
Excisional treatment in women with cervical adenocarcinoma in situ (AIS): a prospective randomised controlled non-inferiority trial to compare AIS persistence/recurrence after loop electrosurgical excision procedure with cold knife cone biopsy: protocol for a pilot study. ( 28851799 )
2017
47
Incidence and survival trends of cervical adenocarcinoma in Italy: Cytology screening has become more effective in downstaging the disease but not in detecting its precursors. ( 27639249 )
2017
48
Adjuvant therapy after radical surgery for stage IB-IIB cervical adenocarcinoma with risk factors. ( 27677664 )
2017
49
Preinvasive and Invasive Cervical Adenocarcinoma: Preceding Low-Risk or Negative Pap Result Increases Time to Diagnosis. ( 27977543 )
2017
50
Increasing incidence of invasive and in situ cervical adenocarcinoma in the Netherlands during 2004-2013. ( 28102052 )
2017

Variations for Cervical Adenocarcinoma

Expression for Cervical Adenocarcinoma

Search GEO for disease gene expression data for Cervical Adenocarcinoma.

Pathways for Cervical Adenocarcinoma

Pathways related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.83 CDKN1A ERBB2 LAMC2 PTGS2 TP53
2
Show member pathways
12.47 CDKN1A CDKN2A CDX2 ERBB2 ESR1 TP53
3
Show member pathways
12.44 CDKN1A CDKN2A ERBB2 ESR1 RASSF1 TP53
4
Show member pathways
12.41 CDKN1A CDKN2A MCM5 TP53
5 12.21 CDKN1A CDKN2A MCM5 TP53
6 12.14 CDKN1A ERBB2 ESR1 TP53
7 12.11 CDKN1A CDKN2A ERBB2 PTGS2 RASSF1 TP53
8 11.95 CDKN1A CDKN2A ERBB2 ESR1 LAMC2 PTGS2
9 11.84 CDKN1A PTGS2 TP53
10 11.83 CDKN1A CDKN2A TP53
11 11.82 CDKN1A CDKN2A ERBB2 TP53
12 11.79 CDKN1A CDKN2A TP53
13
Show member pathways
11.71 CDKN1A ERBB2 ESR1
14 11.67 CDKN1A LAMC2 PTGS2 TP53
15 11.42 CDKN1A CDKN2A ERBB2 TP53
16 11.41 CDKN1A PTGS2 TP53
17 11.39 CDKN1A CDKN2A TP53
18 11.35 CDKN1A ESR1 PTGS2
19 11.22 CDKN1A CDKN2A ERBB2 RASSF1 TP53
20 11.2 ESR1 PTGS2 TP53
21
Show member pathways
10.95 CDKN1A CDKN2A TP53
22 10.66 CDKN1A TP53
23
Show member pathways
10.46 CDKN1A TP53

GO Terms for Cervical Adenocarcinoma

Cellular components related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.02 CDKN1A CDX2 ESR1 PTGS2 TP53

Biological processes related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.85 CDKN2A EBAG9 KRT20 TP53 VIL1
2 cell cycle GO:0007049 9.83 CDKN1A CDKN2A MCM5 RASSF1 TP53
3 negative regulation of cell growth GO:0030308 9.67 CDKN1A CDKN2A TP53
4 G1/S transition of mitotic cell cycle GO:0000082 9.58 CDKN1A CDKN2A MCM5
5 negative regulation of phosphorylation GO:0042326 9.48 CDKN1A CDKN2A
6 cell cycle arrest GO:0007050 9.46 CDKN1A CDKN2A RASSF1 TP53
7 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.37 ESR1 TP53
8 negative regulation of immature T cell proliferation in thymus GO:0033088 9.32 CDKN2A ERBB2
9 signal transduction by p53 class mediator GO:0072331 9.26 CDKN1A TP53
10 Ras protein signal transduction GO:0007265 9.26 CDKN1A CDKN2A RASSF1 TP53
11 replicative senescence GO:0090399 8.8 CDKN1A CDKN2A TP53

Molecular functions related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.62 CDKN1A CDKN2A

Sources for Cervical Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....